Update on emergency contraception.
Emergency contraception provides a critical and time-sensitive opportunity for women to prevent undesired pregnancy after intercourse. Both access and available options for emergency contraception have changed over the last several years.



Emergency contraceptive pills can be less effective in obese women. The maximum achieved serum concentration of levonorgestrel (LNG) is lower in obese women than women of normal BMI, and doubling the dose of LNG (3 mg) increases its concentration maximum, approximating the level in normal BMI women receiving one dose of LNG. Repeated use of both LNG and ulipristal acetate (UPA) is well tolerated. Hormonal contraception can be immediately started following LNG use, but should be delayed for 5 days after UPA use to avoid dampening the efficacy of UPA. The copper intrauterine device (IUD) is the only IUD approved for emergency contraception (and the most effective method of emergency contraception), but use of LNG IUD as emergency contraception is currently being investigated. Accurate knowledge about emergency contraception remains low both for patients and healthcare providers.



Emergency contraception is an important yet underutilized tool available to women to prevent pregnancy. Current options including copper IUD and emergency contraceptive pills are safe and well tolerated. Significant gaps in knowledge of emergency contraception on both the provider and user level exist, as do barriers to expedient access of emergency contraception.
Stanford University, Stanford, California, USA.
Wing Kay
WK
Fok
Paul D
PD
Blumenthal
D000328:Adult; D003267:Contraception; D044363:Contraception, Postcoital / Q000639:trends*; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003281:Contraceptives, Postcoital / Q000008:administration & dosage*; D005260:Female; D006297:Health Services Accessibility; D006801:Humans; D007435:Intrauterine Devices, Copper; D016912:Levonorgestrel / Q000008:administration & dosage; D009649:Norpregnadienes / Q000008:administration & dosage; D009765:Obesity / Q000150:complications; D011247:Pregnancy
D003271:Contraceptive Agents, Female; D003281:Contraceptives, Postcoital; D009649:Norpregnadienes; D016912:Levonorgestrel; C555622:ulipristal acetate